NOV 09, 2016 08:00 AM PST
ProEnkephalin:(PENK). New Biomarker and Novel Window to Kidney Function: Emerging new data of ProEnkephalin in Clinical Populations
SPONSORED BY: Sphingotec LLC
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
3 7 1310

Speakers:
  • Professor of Medicine , UC San Diego Director, Coronary Care Unit and Heart Failure Program, Veterans Affairs San Diego Healthcare System
    Biography
      Dr. Maisel graduated from the University of Michigan Medical School, received his internal medicine training at Michael Reese Hospital in Chicago, and completed a cardiology fellowship at the University of California, San Diego.

      Dr. Maisel is a Professor of Medicine at the University of California, San Diego (UCSD). He is the Director of the Coronary Care Unit and Heart Failure Program at the VA San Diego Healthcare System in La Jolla, California. Dr. Maisel is active on the faculty at UCSD where he has won numerous teaching awards. He just finished a ten-year stint as Associate Editor of the Journal of the American College Cardiology.

      He is considered one of the world's experts on cardiac biomarkers and has over 300 scientific publications. He has authored several ground-breaking publications that have paved the way for development of diagnostic tools for patients with congestive heart failure. In particular, he was the leading investigator on studies that brought the use of BNP into clinical practice.
    • Professor and Chair of Internal Medicine; Lund University
      Biography
        Olle Melander has been main tutor ("huvudhandledare") for 7 completed PhD projects of which all are still active clinicians. Melander was ranked no 1 and was offered the professorship of ‘Cardiovascular Epidemiology' at Karolinska Institute, Stockholm (2010) and the same year he was appointed professor and chair of Internal Medicine at Lund University. He was awarded the prestigious ‘Peter Slight Award' (10 000 euros) June 2010 by the ‘European Society of Hypertension' for his contributions to "prediction and prevention of cardiovascular disease" and the Fernström award (100 000 SEK) of Lund University 2013. In May 2011 he got the Swedish Heart and Lung Foundation large grant ("Hjärt-Lungfondens stora anslag") (15 million SEK), a grant that is only awarded to one Swedish researcher yearly with internationally leading cardiovascular research. In June 2011 he got, in competition with European top researchers, another large grant of 1.5 million euros from the "European Research Council". He was top ranked by the Swedish Research Council (VR) in his review panel group and got 6 million SEK 2015-2018 from VR. In 2016 he was awarded Göran Gustafssons Prize (250 000 SEK) and grant (4 500 000 SEK) as well as Wallenberg Clinical Scholar grant (15 000 000 SEK) both by the Royal Swedish Academy of Science.
      • Professor of Clinical Medicine Director, CREST and MAS in Clinical Research Programs; Division of Nephrology-Hypertension, UC San Diego
        Biography
          Dr. Mehta is a Professor of Medicine in the Division of Nephrology and Associate Chair for Clinical Affairs in the Department of Medicine at the University of California, San Diego (UCSD) where he directs the Clinical nephrology and Dialysis programs. He also serves as the Director of the UCSD Masters in Clinical Research training program that is supported through the NIH K30 mechanism. He is an internationally recognized expert in the field of acute renal failure and has directed several clinical studies in the management of patients with kidney disease including comparing different dialytic modalities in the treatment of acute kidney injury (AKI) conducting large multicenter observational studies of AKI with the PICARD group, evaluating different predictive models for outcomes in AKI, investigating the role of cytokine removal by dialysis membranes in sepsis and AKI, and evaluating techniques for determining the amount of excess fluid in dialysis patients. In addition to his clinical and research activities, he has worked with the American Society of Nephrology, National Kidney Foundation, Society of Critical Care Medicine, and the International Society of Nephrology in developing courses for fellows and practicing physicians in clinical nephrology and dialysis techniques. He chairs the annual International Conference on CRRT that is now in its 13th year. He is also the Chair of the International Society of Nephrology Commission on Acute Kidney Injury, founding member of the Acute Dialysis Quality Initiative and the Acute Kidney Injury network (AKIN) . He is an author or coauthor of several scientific articles, papers and book chapters. He is actively involved in resident and scholar teaching and has won the house staff teaching award on four occasions. In 2003 he was awarded School of Medicine Faculty teaching award. Over the course of his academic career, he has trained over 40 post-doctoral fellows in nephrology, of whom 12 have carried out their research projects.

        Abstract:
        DATE:  November 9, 2016
        TIME:  8:00am PT, 11:00am ET

        This talk will characterize the current clinical and laboratory standards for determining risk for chronic renal dysfunction and acute kidney injury. The SOFA scores, RIFLE criteria, strengths and limitations. The importance of Serum Creatinine as a working laboratory test for renal assessment. The limitations of Serum Creatinine as a real-time tool for renal assessment and prediction/diagnosis of acute kidney injury will be reviewed.

        The importance of timely prediction of AKI and diagnosis/treatment of AKI will be discussed. The potential for novel biomarkers to provide solutions for patient care in this area and the characteristics of an ideal biomarker for AKI will be described.

        A significant emergence of data shows a consistent relationship between the novel biomarker ProEnkephalin (PENK) and renal function. As data continues to accrue in the medical literature the importance of understanding it's clinical context and implications. This webinar will provide an update on Proenkephalin research and clinical findings, as well as perspectives from leading authorities in renal disease and novel biomarker application.

        Learning Objectives:
        • Characterize the current challenges is management of chronic and acute renal disease.
        • Provide an evidence based review of the emergence of ProEnkephalin (PENK) as a renal function biomarker
        • Discuss the clinical implications of the rapidly emerging data associated with PENK in the assessment of renal disease
         

        Show Resources
        Loading Comments...